Format

Send to:

Choose Destination
See comment in PubMed Commons below
Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x.

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

Collaborators (133)

Abbott L, Abelseth J, Alvarado-Ruiz R, Anjani D, Arakaki R, Arechavaleta-Granell M, Austin J, Bailey T, Barrera J, Bertolino J, Bettis R, Blonde L, Bode B, Bressler P, Brusco O, Camacho P, Carroll M, Cartas M, Cefalu W, Cheatham W, Chisolm O, Clarke D, Corbett B, Corder C, Cox M, Crockett S, Cullen E, DeHaven J, Downey H, Duckor S, East H, Farmer H, Farrell J, Feinglo M, Fishman N, Fusco F, García-Hernández P, Garber A, Gilbert J, Gilman R, Goldstein B, Gollapudi G, Gonzalez-Galvez G, Gonzalez-Villalpando C, Graf R, Greco S, Griffing G, Hartman I, Hassman D, Hodge R, Hoffman B, Hollander P, Huffman D, Hunt G, Jain R, Kaplan R, Kapoor A, Kawley A, Klein A, Landgarten S, Leichter S, Leslie H, Licata A, Linden D, Lipetz A, Lochner J, Magee M, Mar-Arevalo F, Mather K, McGill J, Mezitis N, Molitch M, Morales-Flores H, Morris L, Mudaliar S, Mulmed L, Myers L, O'Barr T, Olansky L, Ollins R, Olvera-Alvarez I, Palte S, Pearlstein R, Peterson G, Phillips L, Popeil L, Powers C, Pullman J, Race J, Ratcliff L, Reichman A, Reeves M, Reynolds L, Rios-Rodriguez E, Rivera-Colon L, Robinson M, Rodriguez-Pattzi H, Rosenstock J, Rothman J, Salinas-Gonzalez F, Sauque-Reyna L, Schumacher D, Schwartz S, Seidman B, Sharma S, Shelmet J, Shepherd M, Shomali M, Silver B, Smith T, Snell P, Snyder B, Sosa-Camas R, Sugimoto D, Sussman A, Tamayo R, Tamez-Perez H, Thigpen D, Tisovec R, Trevino M, Violante-Ortiz R, Wahl T, Warren M, Weinrib S, Weinstein R, Weinstock R, Weiss D, Williams R, Winer N, Witkin D, Wittmer B, Zieve F, Zisser H.

Abstract

AIM:

As weight gain and hypoglycaemia associated with glimepiride therapy can negatively impact weight perceptions, psychological well-being and overall quality of life in type 2 diabetes, we investigated whether liraglutide treatment could improve these factors.

METHODS:

Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).

RESULTS:

Mean (SE) decreases in glycated haemoglobin levels were greater with liraglutide 1.2 mg [-0.84 (0.08)%] and 1.8 mg [-1.14 (0.08)%] than glimepiride [-0.51 (0.08)%; p = 0.0014 and p < 0.0001, respectively]. Patients gained weight on glimepiride [mean (SE), 1.12 (0.27) kg] but lost weight on liraglutide [1.2 mg: -2.05 (0.28) kg; 1.8 mg: -2.45 (0.28) kg; both p < 0.0001]. Patient weight assessment was more favourable with liraglutide 1.8 mg [mean (SE) score: 40.0 (2.0)] than glimepiride [48.7 (2.0); p = 0.002], and liraglutide 1.8 mg patients were 52% less likely to feel overweight [odds ratio (OR) 0.48; 95% confidence interval (CI): 0.331-0.696]. Mean (SE) weight concerns were less with liraglutide [1.2 mg: 30.0 (1.2); 1.8 mg: 32.8 (1.2)] than glimepiride [38.8 (1.2); p < 0.0001 and p < 0.001, respectively], with liraglutide groups 45% less likely to report weight concern (OR 0.55, 95% CI: 0.41-0.73). Mean (SE) mental and emotional health and general perceived health improved more with liraglutide 1.8 mg [476.1 (2.8) and 444.2 (3.2), respectively] than glimepiride [466.3 (2.8) and 434.5 (3.2), respectively; p = 0.012 and p = 0.033, respectively].

CONCLUSIONS:

Improved glycaemic control and decreased weight with liraglutide 1.8 mg vs. glimepiride can improve psychological and emotional well-being and health perceptions by reducing anxiety and worry associated with weight gain.

PMID:
20590735
[PubMed - indexed for MEDLINE]
PMCID:
PMC2901519
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Write to the Help Desk